Volume 6.01 | Jan 16

Prostate Cell News 6.01 January 16, 2015
Prostate Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  PCN on Twitter
Transfected Poly(I:C) Activates Different dsRNA Receptors Leading to Apoptosis or Immunoadjuvant Response in Androgen-Independent Prostate Cancer Cells
Researchers characterized the receptors and the signalling pathways involved in the remarkable apoptosis induced by poly(I:C) transfected by lipofectamine compared to twelve-fold higher free poly(I:C) concentration in PC3 and DU145 cells. [J Biol Chem] Abstract | Full Article
New TeSR™-E8™ is Here For Feeder-Free Culture of Human ES Cells and iPS Cells
PUBLICATIONS (Ranked by impact factor of the journal)

LEF1 Targeting EMT in Prostate Cancer Invasion Is Regulated by miR-34a
Investigators describe the molecular mechanism of microRNA-34a (miR-34a) and lymphoid enhancer-binding factor-1 (LEF1) in cooperatively regulating prostate cancer cell invasion. [Mol Cancer Res] Abstract

Hepsin Inhibits CDK11p58 I.E. Activity by Suppressing Unr Expression and eIF-2α Phosphorylation in Prostate Cancer
Scientists found that hepsin inhibited the internal ribosome entry site activity and expression of CDK11p58, which is associated with cell cycle progression and pro-apoptotic signaling in prostate cancer. [Cell Signal] Abstract

FOXO3a Modulates WNT/β-Catenin Signaling and Suppresses Epithelial-to-Mesenchymal Transition in Prostate Cancer Cells
Researchers demonstrate that forkhead box-O (FOXO)3a significantly inhibits the expression β-catenin in prostate cancer cells. The mechanism of inhibiting β-catenin expression involves the FOXO3a-mediated transactivated microRNA-34b/c, which consequently suppressed β-catenin mRNA expression by targeting the untranslated regions of β-catenin. [Cell Signal] Abstract

The Potential of Neurotensin Secreted from Neuroendocrine Tumor Cells to Promote Gelsolin-Mediated Invasiveness of Prostate Adenocarcinoma Cells
Researchers investigated the interactions between neuroendocrine cells and LNCaP cells and the involvement of gelsolin in contributing to the invasive potential of LNCaP cells. [Lab Invest] Abstract

NUSAP1 Expression Is Upregulated by Loss of RB1 in Prostate Cancer Cells
NUSAP1 expression is elevated in the RB1-null DU145 prostate cancer cell line, as opposed to LNCaP and PC-3 cell lines. Furthermore, NUSAP1 expression increases upon knockdown of RB1 in prostate cancer cell lines and decreases after knockdown of E2F1. [Prostate] Abstract

CYP3A5 Regulates Prostate Cancer Cell Growth by Facilitating Nuclear Translocation of AR
Scientists elucidated the mechanism of regulation of androgen receptor (AR) expression by CYP3A5. CYP3A5 siRNA blocked growth of LNCaP and C4-2 cells by 30-60%. [Prostate] Abstract

Adiponectin Inhibits VEGF-A in Prostate Cancer Cells
Prostate cancer cell lines examined had all lower levels of adiponectin and adiponectin receptor I, compared to normal healthy prostate tissue. Moreover, overexpression of adiponectin in prostate cancer cells decreased production of vascular endothelial growth factor A (VEGF-A), while adiponectin depletion increased VEGF-A. [Tumor Biol] Abstract

Oxidized Low-Density Lipoprotein Is Associated with Advanced-Stage Prostate Cancer
Scientists investigated the function of oxidized low-density lipoprotein (ox-LDL) in prostate cancer cell lines in vitro. Phosphorylation protein chips were used to analyze cell signaling pathways in ox-LDL-treated PC-3 cells. [Tumor Biol] Abstract

Inhibitory Action of Pristimerin on Hypoxia-Mediated Metastasis Involves Stem Cell Characteristics and EMT in PC-3 Prostate Cancer Cells
The authors investigated whether pristimerin affects the bone metastasis, stem cell characteristics and epithelial-mesenchymal transition (EMT) of prostate cancer PC-3 cells subjected to hypoxia. [Oncol Rep] Abstract


Radium-223 Dichloride: A Novel Treatment Option for Castration-Resistant Prostate Cancer Patients with Symptomatic Bone Metastases
The authors reviewed and evaluated the clinical trial efficacy and safety of radium 223 along with its place in therapy in men with castration-resistant prostate cancer. [Ann Pharmacother] Abstract

Mutation Detection in Formalin-Fixed Prostate Cancer Biopsies Taken at the Time of Diagnosis Using Next-Generation DNA Sequencing
Scientists assessed whether next-generation DNA sequencing can be used to screen prostate cancer for multiple gene alterations in men routinely diagnosed with this disease and/or who are entered into clinical trials. [J Clin Pathol] Abstract

Listen Now: Podcast on ALDH in Breast Cancer Treatment Response
Immunotherapy for Castration-Resistant Prostate Cancer: Progress and New Paradigms
The authors describe the rationale for immunotherapy for prostate cancer, summarize the approaches under evaluation, and discuss sequencing options for immunotherapy in the current treatment paradigm. [Urol Oncol] Full Article

Visit our reviews page to see a complete list of reviews in the prostate cell research field.
Prostate Cancer Foundation Announces 6 New Challenge Awards for New Discoveries in Treatment Sciences
The Prostate Cancer Foundation (PCF) announced six new Challenge Awards to advance the treatment of lethal prostate cancer. PCF Challenge Awards are multi-year awards supporting cross-disciplinary teams of research scientists. $39 million went toward supporting research programs in 2014. [Prostate Cancer Foundation]
Press Release

OncoGenex Announces Update on Phase III AFFINITY Trial Evaluating Custirsen in Men with Metastatic Castrate-Resistant Prostate Cancer
OncoGenex Pharmaceuticals, Inc. announced that the AFFINITY trial is continuing as planned based upon completion of the interim futility analysis and the recommendation of the Independent Data Monitoring Committee. [OncoGenex Pharmaceuticals, Inc.] Press Release

New wallchart from our sponsor:
Mesenchymal Stem Cells (a Nature Reviews Molecular Cell Biology collaboration).
Request your free copy.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW CIRM 2.0 Free Webinar – Changing the Way We Work
January 21, 2015, 12:00 PM PST

NEW 2nd International Congress on Stem Cell and Cellular Therapies (ICSCCT)
October 15-18, 2015
Antalya, Turkey

Visit our events page to see a complete list of events in the prostate cell community.
NEW Director (California Institute for Regenerative Medicine)

Postdoctoral Research Fellow – Post-Transcriptional Gene Regulation Governing Cancer Cell Behavior (Fred Hutchinson Cancer Research Center)

Postdoctoral Fellow – Wnt Signaling in Development and Disease (Van Andel Research Institute)

Postdoctoral Fellow – Prostate Cancer Epigenetics and Genomics (UT Southwestern)

PhD Studentship – Chemokine Receptor in Prostate Cancer Metastasis (University of East Anglia)

Postdoctoral Position – Prostate Cell Biology (CEA/Grenoble )

Postdoctoral Research Associate Positions – Cancer Biology (Hollings Cancer Center)

Postdoctoral Position – Molecular Mechanisms and Translational Investigations of Advanced Prostate Cancer (Cleveland Clinic)

Postdoctoral Researcher – Chromatin and Epigenetic Regulation (Van Andel Research Institute)

Research Technologist – Media Development (STEMCELL Technologies Inc.)

Scientist – Prostate Cell Research (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Prostate Cell News: Archives | Events | Contact Us